SunMax Biotechnology Co. Ltd.

As of June 30, 2026, SunMax Biotechnology Co. Ltd. carries a market capitalization of 20.61B, placing it among publicly traded companies globally. Its enterprise value stands at 19.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SunMax Biotechnology Co. Ltd. has 54.46M shares outstanding.

As of June 30, 2026, SunMax Biotechnology Co. Ltd. trades at a trailing price-to-earnings ratio of 25.41. The price-to-sales ratio is 9.39, and the price-to-book ratio stands at 14.41.

As of June 30, 2026, SunMax Biotechnology Co. Ltd. trades at an EV/EBITDA multiple of 16.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. SunMax Biotechnology Co. Ltd. trades at an EV/FCF ratio of 23.04, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 19.93B versus a market cap of 20.61B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SunMax Biotechnology Co. Ltd. maintains a current ratio of 2.55, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.57, indicating elevated leverage, while an interest coverage ratio of 273.01 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SunMax Biotechnology Co. Ltd. posted a return on equity (ROE) of 60.67, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 50.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 36.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 55.95, useful for judging operating efficiency across full business cycles. The company generates approximately 22.86M in revenue per employee across its workforce of 96.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.61 indicates how many times SunMax Biotechnology Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SunMax Biotechnology Co. Ltd. recorded 308.02M in income tax expense. That works out to an effective tax rate of 27.51, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.12B, leaving 811.53M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 21, 2026, SunMax Biotechnology Co. Ltd.'s stock has gained approximately 0.38% over the past 52 weeks. The 50-day moving average sits at 393.29, while the 200-day moving average is 389.53.

Over the twelve months ended June 30, 2026, SunMax Biotechnology Co. Ltd. generated 2.19B in revenue and converted that into 811.53M in net income, yielding earnings per share of 14.88. EBITDA reached 1.21B, while operating income came in at 1.09B.

As of June 30, 2026, SunMax Biotechnology Co. Ltd. holds 793.19M in cash and equivalents against 108.37M in total debt, resulting in a net debt position of -430.47M. Total book value stands at 1.43B, with working capital of 626.73M providing operational flexibility.

SunMax Biotechnology Co. Ltd. produced 959.28M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -97.54M in capital expenditures, free cash flow totaled 861.74M - equivalent to 15.82 per share.

Over the twelve months ended June 30, 2026, SunMax Biotechnology Co. Ltd. posted a gross margin of 79.07, reflecting its pricing power and cost economics. The operating margin of 49.82 and net profit margin of 36.97 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, SunMax Biotechnology Co. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.18, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.41, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SunMax Biotechnology Co. Ltd. shareholders.

SunMax Biotechnology Co. Ltd.'s most recent stock split took place on May 7, 2010 with a 839:908 split ratio.

As of June 30, 2026, SunMax Biotechnology Co. Ltd. has an Altman Z-Score of 25.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.